Literature DB >> 10086483

Treatment options for refractory depression.

R C Shelton1.   

Abstract

A significant proportion of patients with depressive disorders do not experience a full response with antidepressant treatment. Fortunately, most eventually remit, even though the time to response may be significantly delayed in many patients. A variety of options exist to deal with these difficult clinical situations. Established strategies include switching to an antidepressant of an alternative class (e.g., tricyclic to a monoamine oxidase inhibitor [MAOI] or selective serotonin reuptake inhibitor [SSRI]), electroconvulsive therapy (ECT), and augmentation with lithium or thyroid hormone. Promising alternatives include combined serotonin and norepinephrine enhancement strategies (e.g., SSRI plus serotonin norepinephrine reuptake inhibitor [NSRI] or higher doses of venlafaxine or fluoxetine), steroid suppression therapy, augmentation with atypical antipsychotics, and psychotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086483

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  Thyroid Augmentation of Mirtazapine: A Case Report.

Authors:  Timothy R. Berigan; Karl N. Zeff
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-02

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  Clinical and demographic predictors of symptoms of depression and anxiety in patients with spinal cord injury.

Authors:  Ana Clara Portela Hara; Nicole C Aching; Lucas M Marques; Felipe Fregni; Linamara R Battisttella; Marcel Simis
Journal:  Spinal Cord       Date:  2022-07-15       Impact factor: 2.473

4.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Authors:  William V Bobo; Richard C Shelton
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

5.  Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex.

Authors:  Mei Huang; Junji Ichiwaka; Zhu Li; Jin Dai; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

Review 6.  Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.

Authors:  Marc Kelliny; Paul E Croarkin; Katherine M Moore; William V Bobo
Journal:  Ther Clin Risk Manag       Date:  2015-08-12       Impact factor: 2.423

7.  Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition.

Authors:  Eunsoo Won; Seon-Cheol Park; Kyu-Man Han; Seung-Hwan Sung; Hwa-Young Lee; Jong-Woo Paik; Hong Jin Jeon; Moon-Soo Lee; Se-Hoon Shim; Young-Hoon Ko; Kang-Joon Lee; Changsu Han; Byung-Joo Ham; Joonho Choi; Tae-Yeon Hwang; Kang-Seob Oh; Sang-Woo Hahn; Yong-Chon Park; Min-Soo Lee
Journal:  J Korean Med Sci       Date:  2014-04-01       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.